{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE+%28insulin+glargine%29&page=2", "query": { "intervention": "Lantus® (insulin glargine)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE+%28insulin+glargine%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE+%28insulin+glargine%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T13:25:17.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03107208", "title": "Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Ketoacidosis", "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Glargine", "type": "DRUG" }, { "name": "Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 61, "start_date": "2017-07-21", "completion_date": "2021-03-13", "has_results": true, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107208" }, { "nct_id": "NCT01919489", "title": "Liraglutide Hospital Discharge Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Liraglutide + OADs", "type": "DRUG" }, { "name": "Glargine + OADs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 273, "start_date": "2014-03", "completion_date": "2020-08-30", "has_results": true, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 5, "location_summary": "Miami, Florida • Atlanta, Georgia • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01919489" }, { "nct_id": "NCT01194258", "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type II" ], "interventions": [ { "name": "Insulin lispro", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin glulisine", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2010-08", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-08-20", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 22, "location_summary": "Concord, California • Encino, California • Escondido, California + 18 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194258" }, { "nct_id": "NCT01357603", "title": "Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type1 Diabetes" ], "interventions": [ { "name": "Glargine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wockhardt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 111, "start_date": "2011-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01357603" }, { "nct_id": "NCT00240253", "title": "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "pramlintide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 200, "start_date": "2005-10", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2015-03-31", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00240253" }, { "nct_id": "NCT02455076", "title": "Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Rapid-acting insulin analogs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 150, "start_date": "2015-09", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2019-06-20", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455076" }, { "nct_id": "NCT01196104", "title": "Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Technosphere® Insulin Inhalation Powder", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 39, "start_date": "2010-09", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2014-10-30", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 29, "location_summary": "Mobile, Alabama • Fresno, California • Long Beach, California + 22 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01196104" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT00751114", "title": "Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "35 Years to 70 Years" }, "enrollment_count": 515, "start_date": "2008-11", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00751114" }, { "nct_id": "NCT02302716", "title": "A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2963016", "type": "DRUG" }, { "name": "LANTUS®", "type": "DRUG" }, { "name": "Oral Antihyperglycemic Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2014-12", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-10-24", "last_synced_at": "2026-10-10T13:25:17.356Z", "location_count": 10, "location_summary": "Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Smyrna", "state": "Georgia" }, { "city": "Topeka", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302716" } ] }